Australian Court Approves Qiagen's Purchase of Cellestis Shares | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellestis announced on Tuesday that the Supreme Court of Victoria in Australia has approved Qiagen's acquisition of its ordinary shares by way of a Scheme of Arrangement.

Upon implementation of the Scheme, Cellestis shareholders will received cash consideration of A$3.80 ($3.90) per share, comprised of A$3.73 in cash from Qiagen for each Cellesis share, and a special dividend of A$.07 per Cellestis share, Qiagen said separately.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.